New combo therapy aims to stop lung cancer's return after surgery
NCT ID NCT07320105
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding radiotherapy to immunotherapy after surgery can help people with a certain type of advanced lung cancer (stage III N2 non-small cell lung cancer) live longer without the cancer coming back. About 60 adults aged 18 to 75 who have had surgery and have cancer in at least three lymph nodes will take part. The goal is to see if this combination is safe and effective at delaying disease progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fujian Provincial Cancer Hospital
RECRUITINGFuzhou, Fujian, 350014, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?